BROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare expertise firm leveraging biomarkers and proprietary augmented intelligence (AI) algorithms by its Nociscan platform to assist physicians determine the situation of power low again ache and assist improved remedy success charges, at the moment introduced that its Board of Administrators has approved a share repurchase program of as much as $2.5 million of the Firm’s excellent widespread inventory.
Aclarion expects to execute the repurchase program over the following 12 months. The timing, quantity, and nature of repurchases can be decided by the Firm based mostly on elements together with market situations, share value, liquidity, and operational and strategic priorities. This system doesn’t obligate the Firm to amass any particular variety of shares, and could also be suspended, modified, or discontinued at any time.
The Firm intends to fund the repurchase program utilizing current money and money equivalents.
“This authorization underscores our commitment to disciplined capital allocation and our belief that Aclarion’s current valuation does not fully reflect the strength of our platform and long-term growth opportunity,” mentioned Brent Ness, Chief Government Officer of Aclarion. “We believe our shares represent a compelling value at current levels, and we view this program as a flexible and opportunistic tool to enhance shareholder value while continuing to invest in the clinical adoption and expansion of Nociscan.”
As of March 31, 2026, the Firm had money and money equivalents of roughly $19.0 million, which administration believes offers adequate runway to assist operations by key upcoming milestones, together with the preliminary milestone of the CLARITY randomized trial.
More Read
Greg Gould, Chief Monetary Officer of Aclarion, added, “We are focused on balancing investment in growth with prudent capital management. Given our current capital position and expected operating needs, we believe a share repurchase program is an efficient and disciplined way to deploy capital while maintaining the financial flexibility necessary to execute on our strategic priorities.”
Repurchases underneath this system could also be made every so often, in quantities, at costs, and at such instances because the Firm deems acceptable, topic to market situations and different concerns, in compliance with relevant federal and state securities legal guidelines, together with Guidelines 10b5-1 and 10b-18 underneath the Securities Trade Act of 1934, as amended. Repurchases could also be executed by a wide range of strategies, together with open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, or pursuant to Rule 10b5-1 buying and selling plans, which can allow the Firm to repurchase shares during times when it might in any other case be restricted from doing so.
To discover a Nociscan heart, view our web site map right here.
More Read
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar backbone. By way of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers crucial insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch comprises forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic info, equivalent to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to plenty of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. Ahead-looking statements on this launch embody, amongst others, statements relating to the expectation to execute the repurchase program over the following 12 months, that the Firm intends to fund the repurchase program utilizing current money and money equivalents, administration’s perception that the $19.0 million at March 31, 2026 offers adequate runway to assist operations by key upcoming milestones, together with the preliminary milestone of the CLARITY randomized trial, and the potential advantages of our Nociscan expertise. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Trade Fee. Readers are inspired to evaluate the part titled “Risk Factors” within the Firm’s Annual Report on Kind 10-Ok for the 12 months ended December 31, 2025, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Investor Contacts:
Media Contacts:
